Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Rizk Elbaz
Total Records ( 2 ) for Rizk Elbaz
  Magdy M. Youssef, , Amal Elshaer , Rizk Elbaz , Yehia A. Ellazek , Ahmad El-Waseef and Ahmad Settin
  Background and Objective: Apolipoprotein C3 (APOC3) is a component of triglyceride-rich lipoproteins and APOC3 gene polymorphisms have been associated with non-alcoholic fatty liver disease (NAFLD), hypertriglyceridaemia and insulin-resistance. This study was undertaken to determine if the APOC3 gene variants were associated with the susceptibility of obese subjects to develop liver damage, hypertriglyceridaemia and insulin-resistance. Materials and Methods: The study was carried out on 100 unrelated obese Egyptians. These cases were compared to 83 normal weight healthy controls. All participants were subjected to an estimation of their body mass index (BMI) in addition to liver functions and lipid profile. Polymerase chain reaction Polymerase chain reaction with sequence-specific primers (SSP-PCR) was performed to detect the of APOC3 rs2854116 and rs2854117 polymorphic genotypes. Results: Cases showed a significantly higher frequency of the APOC3 T-455C, CC genotype than controls (32 vs. 9.6%, p = 0.0003, Odds ratio = 5.33, 95% CI = 2.2-12.7). In addition, the allelic frequency of the rare APOC3 -455 C allele was significantly higher among cases than controls (51 vs. 30.72%, p = 0.0001, OR = 2.35, 95% CI = 1.5-3.6). On the other hand cases showed a non-significant difference regarding all APOC3 C-482T genotypes (CT vs. CC, TT vs. CC and CT+TT vs. CC) as well as APOC3 -482 T vs. C alleles. All cases showed no significant difference of their hematologic, liver functions and lipid profile related to their genetic polymorphism. Conclusion: The polymorphism T-455C but not the C-482T in APOC3 gene was associated with NAFLD in Egyptian obese subjects. However, it did not affect their hematologic, liver and lipid profile parameters.
  Ahmed Hendawy , Mansour Hasan , Rizk Elbaz , Ghada El-Kannishy , Saad Elshaer and Ahmed Settin
  Genetic predisposition has been implicated in obesity. Lipoprotein lipase (LPL) gene, the main lipase of chylomicrons and Low Density Lipoproteins (LDL), has a fundamental role in the transport and metabolism of plasma cholesterol. The present study was undertaken to test for the association of the LPL gene Pvu II polymorphism with obesity with or without hypertension and diabetes and dyslipidemia among affected Egyptian cases. This study has included 120 subjects affected with obesity; 57 of them were affected with metabolic syndrome (with diabetes, dyslipidemia and hypertension) while the other 63 cases were not complicated and were termed “simple obesity”. These cases were compared to 83 healthy non-obese controls. Body Mass Index (BMI), Waist Hip Ration (WHR) and serum lipid levels were measured. The LPL gene polymorphic alleles were determined by PCR-RFLP that includes polymerase chain reaction for gene amplification followed by digestion with Pvu II enzyme and analysis according to the size of digested amplified DNA. Obesity cases had a significantly higher frequency of the homozygous mutated LPL Pvu II (+/+) genotype and also of the (+) allele particularly among metabolic syndrome cases compared to controls. Cases with the (+/+) homozygous genotype showed significantly higher frequency of diabetes, lower frequency of positive family history and lower values for waist hip ratio than those with the (+/-) and (-/-) genotypes. These cases have showed also higher levels of total cholesterol and LDL-C, yet not reaching statistical significance. This study showed a significant association between the LPL Pvu II gene polymorphism and obesity among Egyptian cases particularly when complicated with the metabolic syndrome.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility